OPTICALLY-ACTIVE BENZAMIDES AS PREDICTIVE TOOLS FOR MAPPING THE DOPAMINE D2 RECEPTOR

被引:26
作者
ROGNAN, D
SOKOLOFF, P
MANN, A
MARTRES, MP
SCHWARTZ, JC
COSTENTIN, J
WERMUTH, CG
机构
[1] INSERM, CTR PAUL BROCA, UNITE NEUROBIOL 109, F-75014 PARIS, FRANCE
[2] UER MED, UNITE NEUROPSYCHOPHARMACOL EXPTL, F-76800 ST ETIENNE DU ROUVRAY, FRANCE
[3] CNRS, CTR NEUROCHIM, DEPT PHARMACOCHIM MOLEC, F-67084 STRASBOURG, FRANCE
来源
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION | 1990年 / 189卷 / 01期
关键词
DOPAMINE D2 RECEPTOR; COMPUTER GRAPHICS; BENZAMIDES; STEREOSELECTIVITY;
D O I
10.1016/0922-4106(90)90230-U
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Substituent variations on the pyrrolidinyl nitrogen of sulpiride, a selective D2 dopamine antagonist, showed that in vitro and in vivo activities are concentrated in the (S) optical series for N-alkyl analogs and in the (R) series for N-benzyl analogs. To account for these unusual structure-activity relationships, a pharmacophoric model was built from the crystallographic structure of (-)piquindone and extended to 14 other D2 antagonists. This model considers the lone pair orientation of the basic nitrogen rather than its spatial location. Two distinct active conformations for benzamides were defined, corresponding to the (S) and (R) series. An extended pharmacophore is then proposed involving four main anchoring areas: (i) an aromatic site Ar1, (ii) a tertiary nitrogen with its lone pair orthogonal to the Ar1 plane, (iii) a dipole DELTA-1 coplanar to the Ar1 ring and (iv) three sites for the N-substituent, including a small hydrophobic pocket and two different aromatic binding sites Ar2 and Ar3. To probe the predictive value of this model, structures were designed and several compounds were synthesized and tested as inhibitors of [I-125]iodosulpride binding to rat striatal membranes and as antagonists of apomorphine-induced stereotyped behavior in mice.
引用
收藏
页码:59 / 70
页数:12
相关论文
共 49 条
  • [31] NISHIKORI K, 1980, J BIOL CHEM, V255, P909
  • [32] A DOPAMINE RECEPTOR MODEL AND ITS APPLICATION IN THE DESIGN OF A NEW CLASS OF RIGID PYRROLO[2,3-G]ISOQUINOLINE ANTI-PSYCHOTICS
    OLSON, GL
    CHEUNG, HC
    MORGAN, KD
    BLOUNT, JF
    TODARO, L
    BERGER, L
    DAVIDSON, AB
    BOFF, E
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1981, 24 (09) : 1026 - 1034
  • [33] A THEORETICAL CONFORMATIONAL STUDY OF SUBSTITUTED ORTHO-ANISAMIDES AS MODELS OF A CLASS OF DOPAMINE ANTAGONISTS
    PANNATIER, A
    ANKER, L
    TESTA, B
    CARRUPT, PA
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1981, 33 (03) : 145 - 149
  • [34] NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA-RECEPTOR BINDING-SITES IN RAT-BRAIN
    PEROUTKA, SJ
    UPRICHARD, DC
    GREENBERG, DA
    SNYDER, SH
    [J]. NEUROPHARMACOLOGY, 1977, 16 (09) : 549 - 556
  • [35] CONFORMATIONS OF SOME SEMI-RIGID NEUROLEPTIC DRUGS .1. CRYSTAL-STRUCTURES OF LOXAPINE, CLOZAPINE, AND HUF-2046 MONOHYDRATE [2-CHLORO-11-(4-METHYLPIPERAZIN-1-YL)DIBENZO[B,F][1,4]OXAZEPINE, 8-CHLORO-11-(4-METHYLPIPERAZIN-1-YL)DIBENZO[B,E][1,4]DIAZEPINE, AND 2-CHLORO-11-(4-METHYLPIPERAZIN-1-YL)DIBENZO[B,E][1,4]DIAZEPINE MONOHYDRATE
    PETCHER, TJ
    WEBER, HP
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1976, (12): : 1415 - 1420
  • [36] CRYSTAL AND MOLECULAR-STRUCTURE OF HALOPERIDOL, A POTENT PSYCHOTROPIC-DRUG
    REED, LL
    SCHAEFER, JP
    [J]. ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1973, 29 (SEP15): : 1886 - 1890
  • [37] SYNTHESIS OF S-[H-3]-DO-710, A BENZAMIDE LIGAND OF THE D2-DOPAMINE RECEPTOR AND OF S-[H-3]-AZIDOSULPRIDE, ITS PHOTOACTIVABLE ANALOG
    ROGNAN, D
    MANN, A
    HAMDI, P
    WERMUTH, CG
    SOKOLOFF, P
    SCHWARTZ, JC
    ROY, J
    MORGAT, JL
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1987, 24 (11) : 1361 - 1372
  • [38] NEUROLEPTIC ACTIVITY OF CHIRAL TRANS-HEXAHYDRO-GAMMA-CARBOLINES
    SARGES, R
    HOWARD, HR
    DONAHUE, KM
    WELCH, WM
    DOMINY, BW
    WEISSMAN, A
    KOE, BK
    BORDNER, J
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (01) : 8 - 19
  • [39] SCHWARTZ JC, 1984, CATECHOLAMINES NEURO, P59
  • [40] SEEMAN P, 1985, MOL PHARMACOL, V28, P391